Filing Flows › Corcept Therapeutics (CORT) › Q2 2026 › vs Q1 2026
Corcept Therapeutics (CORT) Q2 2026 vs Q1 2026 (quarter over quarter)
Corcept Therapeutics's revenue rose $91.2M (+55%) from $165M in Q1 2026 to $256M in Q2 2026. Operating margin 16.1% against -30.1% (+46.2 pts).
Corcept Therapeutics, Q2 2026: revenue $256M (+32% year over year), operating margin 16.1%, net earnings $43.0M, operating cash flow $33.5M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 16.1% | -30.1% | +46.2 pts |
| Net margin | 16.8% | -19.3% | +36.0 pts |
| Free cash flow margin | 12.1% | -10.3% | +22.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $256M | $165M | $91.2M | +55% |
| Other income, net | $4.6M | $4.9M | −$255K | -5% |
| Operating profit | $41.3M | −$49.6M | $90.9M | — |
| Costs & expenses | $215M | $215M | $343K | +0.2% |
| Pre-tax earnings | $45.9M | −$44.7M | $90.6M | — |
| Cost of revenue | $4.1M | $2.9M | $1.2M | +41% |
| Research & development | $53.9M | $66.3M | −$12.4M | -19% |
| SG&A | $157M | $145M | $11.5M | +8% |
| Net earnings | $43.0M | −$31.8M | $74.7M | — |
| Income tax | $2.9M | −$13.0M | $15.9M | — |
| Depreciation & amortization | $863K | $598K | $265K | +44% |
| Share-based compensation | $29.4M | $23.0M | $6.4M | +28% |
| Working capital & other | $39.7M | $8.7M | $31.1M | +359% |
| Operating cash flow | $33.5M | −$16.8M | $50.3M | — |
| Free cash flow (OCF − capex) | $31.0M | −$17.0M | $48.0M | — |
| Capital expenditures | $2.5M | $201K | $2.3M | 13× |
Questions
How much did Corcept Therapeutics's revenue grow quarter over quarter in Q2 2026?
Corcept Therapeutics's revenue rose $91.2M (+55%) from $165M in Q1 2026 to $256M in Q2 2026. Operating margin 16.1% against -30.1% (+46.2 pts).